- Home
- TCI vs PROK Comparison
TCI vs PROK Comparison
Compare TCI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCI | PROK |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 296.8M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TCI | PROK |
|---|---|---|
| Price | $38.17 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 3.3K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $49,060,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.99 | ★ N/A |
| Revenue Growth | 4.23 | ★ 1075.00 |
| 52 Week Low | $27.06 | $0.54 |
| 52 Week High | $59.65 | $7.13 |
Technical Indicators
Market Signals| Indicator | TCI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 42.25 |
| Support Level | $33.50 | $1.71 |
| Resistance Level | $42.76 | $2.58 |
| Average True Range (ATR) | 1.22 | 0.12 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 33.38 | 1.39 |
Price Performance
Historical ComparisonAbout TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.